Canaccord raised the firm’s price target on Insulet (PODD) to $432 from $428 and keeps a Buy rating on the shares. The firm updated its model to reflect the 2025-2028 financial outlook plan, which outlines revenue, adjusted operating margin, adjusted EPS, and free cash flow guidance for the company.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Early notable gainers among liquid option names on November 21st
- Insulet price target raised to $412 from $390 at Truist
- Insulet price target raised to $380 from $370 at RBC Capital
- Insulet price target raised to $380 from $370 at BTIG
- Insulet’s Promising Growth Potential: A Buy Rating Despite Market Skepticism